Cirqle Biomedical, a Copenhagen, Denmark-based next generation contraceptive company, secured $1.8M in funding.
The round was co-led by BioInnovation Institute (BII) and Rhia Ventures.
The company intends to use the funds for pre-clinical development of a novel non-hormonal contraceptive technology.
Led by Frederik Petursson Madsen, CEO, and Thomas Crouzier, Chief Science Officer, Cirqle Biomedical is a pre-clinical stage biotechnology startup advancing a new approach to contraception that leverages the natural barrier properties of cervical mucus. Using technology developed in a lab at the Royal Institute of Technology in Stockholm, Sweden, the company develops a topically-applied biopolymer that makes cervical mucus impenetrable to sperm cells throughout a woman’s cycle.
This approach can enable a product providing protection instantly and for extended periods without the systemic side-effects known from hormonal contraceptives.